STACK · ↻ Rotation cycle · 3 tiers
Longevity & Cellular Health.
Tune the clocks, rebuild the engines.
Cadence · 10-20 day pulse, 4-6 months off-cycle, 1-2x per year
Hook facts
The science, in one line each.
In a 12-year human study, elderly patients who received Epitalon and Thymalin annually for 6 years had 4.1× lower mortality than the control group — the largest mortality reduction ever recorded for a therapeutic peptide in human trials.
When Thymalin was combined with Epitalon and given annually for 6 consecutive years to elderly patients, all-cause mortality dropped 4.1-fold — meaning for every 4 deaths in the control group, only 1 occurred in the treated group. No pharmaceutical drug has come close to this number in a human aging trial.
When to skip it
Read this first.
This stack is not designed for people with active metabolic disease, uncontrolled insulin resistance, or significant hormonal dysregulation — those conditions need to be addressed first before layering peptides. It also won't deliver meaningful results to people who are metabolically unhealthy and hoping the peptides will compensate; MOTS-c in particular amplifies a working foundation rather than replacing one.
Always cleared with your concierge before protocol start.
Why this works
The strongest evidence.
Epitalon has one of the most robust preclinical longevity datasets of any peptide — controlled animal studies show direct telomerase activation in human somatic cells and lifespan extension effects in multiple rodent models. Khavinson and colleagues at the St Petersburg Institute of Bioregulation documented both Epitalon and Thymalin in long-term gerontology trials, including a female rat model showing stronger anti-aging outcomes from the combination than from either peptide alone. MOTS-c has entered Phase I clinical trials for hepatic steatosis, with preclinical data confirming it functions as a mitochondrial-derived hormone that migrates to the cell nucleus to regulate metabolic stress responses — a mechanism not previously attributed to mitochondria-encoded molecules. SS-31 (elamipretide) has advanced to Phase 2/3 trials in cardiac contexts, where its cardiolipin-binding mechanism has been most rigorously characterised.
Rotation cycle
Cycle through these.
These run in turn, not in parallel — each phase has its own purpose, and pauses between phases are part of the protocol.
Cellular Reset
Cadence — 10-20 day pulse, 4-6 months off-cycle, 1-2x per year
Two peptides, two clocks. Epitalon activates telomerase and resets circadian output via the pineal gland — its nighttime administration is deliberate, tied to melatonin timing. Thymalin, developed within the Russian bioregulator lineage (Khavinson, St Petersburg Institute), drives thymic restoration and immune cell repopulation — addressing the immune-senescence that accumulates silently from the mid-30s onward. Run together as a 10–20 day annual pulse with 4–6 months off-cycle: the same structure used in longevity clinics for over three decades.
Who it's for
Users who want the lowest-commitment longevity protocol — once-yearly 10–20 day pulses. Particularly strong for sleep quality issues, age-related immune decline, and circadian disruption.
What to expect
Improved sleep depth and morning energy within the first cycle. Epitalon's circadian-reset effect typically expresses within 7–10 days. Thymalin's thymic and immune effects accumulate across 1–2 annual cycles.
Mitochondrial Reboot
Cadence — 8-12 week cycle
Three agents, three nodes of the same mitochondrial system — structure, signal, and fuel. SS-31 binds cardiolipin in the inner mitochondrial membrane, protecting its structural integrity under oxidative load. MOTS-c, a mitochondrial-derived peptide, activates AMPK and improves insulin sensitivity, retraining how cells read and respond to metabolic signals. NAD-300 replenishes the redox cofactor that sirtuins and PARP enzymes require to run cellular repair. Together they run as an 8–12 week cycle targeting every major node of mitochondrial decline.
Who it's for
Users with energy complaints, post-illness fatigue, metabolic slowdown, or training recovery plateaus. Run as a dedicated 8–12 week protocol, 1–2 times per year.
What to expect
Improved exercise endurance and reduced afternoon fatigue by week 2–3. Metabolic efficiency gains (better fat oxidation, more consistent energy) become pronounced by week 6–8, driven by MOTS-c's AMPK activation and SS-31's mitochondrial membrane stabilisation.
Healthspan
Cadence — Bioregulator pulse then Mito cycle then rest, year-long rotation
The full rotation is structured around two distinct sub-protocols alternated through the year — not concurrent use. Bioregulator months run Epitalon and Thymalin as a short pulse to reset telomere biology and thymic immune output. Mito months run SS-31 (structure), MOTS-c (signal), NAD-300 (fuel), and Humanin — a second mitochondrial-derived peptide with anti-apoptotic and neuroprotective properties that anchors the cytoprotective layer. Each protocol reinforces the other; neither is meant to run year-round. Rotate, rest, repeat.
Who it's for
Users running a year-long longevity protocol who want to cover every major aging axis. Humanin adds anti-apoptotic neuroprotection and cytoprotection that completes the mitochondrial picture. Typically rotated: Bioregulator pulse in months 1–3, Mito cycle in months 4–6, rest period, repeat.
What to expect
Multi-cycle use compounds benefits: improved immune markers, better biological age measurements, sustained energy and cognitive clarity. Most meaningful outcomes emerge after 2–3 complete annual rotations, with each sub-protocol reinforcing the gains from the last.
The science
Peer-reviewed findings.
Key research findings from the compounds in this stack.
In a 12-year longitudinal clinical trial at two independent Russian and Ukrainian gerontological centers (n=266 elderly patients), Thymalin + Epithalamin treatment reduced all-cause mortality 2.5-fold and cardiovascular mortality by approximately 45%; annual combined treatment over 6 years achieved a 4.1-fold mortality reduction versus controls
SOURCE · Khavinson VK & Morozov VG, Neuroendocrinology Letters, 2003
Epitalon induced a 33% increase in telomere elongation in human somatic cell cultures by upregulating hTERT expression and telomerase enzymatic activity — confirmed in PMC-published research using quantitative telomere length measurement alongside telomerase activity assays
SOURCE · Araj et al., PMC12411320, 2025; Khavinson VK et al., Bull Exp Biol Med, 2003
In the longest human clinical trial ever conducted on a therapeutic peptide, 266 elderly patients (age 60+) followed for 6–8 years at two independent Russian and Ukrainian gerontological institutes showed 2.0–2.1-fold mortality reduction with Thymalin alone; combined annual Thymalin + Epithalamin treatment for 6 years achieved a 4.1-fold mortality reduction vs controls
SOURCE · Khavinson VK & Morozov VG, Neuroendocrinology Letters 24(3-4), 2003; Khavinson et al., PubMed PMID 12577695, 2002
Thymalin treatment in organotypic spleen tissue cultures increased tissue growth zone indices by 20–50%, stimulated lymphocyte proliferation, and reduced apoptosis by 29–42% — providing in vitro mechanistic evidence for its immunoregeneration effects
SOURCE · Anisimov VN & Khavinson VK, meta-analysis review 2010; PeptideInsight research summary
Protocol
How to run it.
Frequency
Epitalon: 10 mg nightly for 10 consecutive days, then 4 months off. Maximum 3 cycles per year. Thymalin: 10 mg daily for 10 days, 1–2 cycles per year alongside Epitalon. MOTS-c: 5 mg every 5 days (4 injections = 1 full cycle of 20 days), or a conservative protocol of 1 mg, 5 days on / 2 days off for 8 weeks. SS-31: 2–4 mg subcutaneous, 2–3x per week during the Mito cycle. NAD-300: daily or near-daily dosing throughout the Mito cycle, as a redox substrate rather than a pulsed peptide. Humanin: low-frequency protocol under physician guidance, typically 2–3x per week within the full rotation.
Duration
Bioregulator protocols are short and infrequent — 10–20 active days per cycle, 4–6 months off. The Mito stack runs 8–12 weeks on, 8 weeks off. The full longevity stack is structured as a year-long rotation across both sub-protocols rather than concurrent use, allowing each system to respond and recover before the next cycle begins.
Timing
Epitalon: inject before bed, at least 2 hours after your last meal — its mechanism is tied to the pineal gland and melatonin regulation, making nighttime administration important. Thymalin: morning administration is standard in most clinical protocols. MOTS-c: before exercise or first thing in the morning, as it enhances mitochondrial energy output and exercise capacity. SS-31: timing is flexible; pre-exercise administration is common given its role in preserving mitochondrial membrane integrity under metabolic stress. NAD-300: morning dosing preferred.
Cycling
No compound in this stack is run continuously. Epitalon and Thymalin: 10–20 days on, 4–6 months off, 1–2 cycles per year. MOTS-c and SS-31: 8–12 weeks on, 8 weeks off. The full rotation sequences Bioregulator months first, then Mito months, then rest — protocols are designed to avoid receptor saturation and allow natural regulatory systems to remain responsive between cycles.
Who it's for
Your profile.
People over 35 who are proactively investing in their biological age rather than waiting for decline to become symptomatic. The ideal candidate is someone who already sleeps reasonably well, exercises consistently, and eats well — but wants to operate at the cellular level rather than just the lifestyle level. This stack is especially relevant for those experiencing early signs of metabolic slowdown, declining energy despite good habits, poor sleep quality, or a sense that recovery from training or illness takes longer than it used to. It's also a strong fit for anyone tracking biological age markers — epigenetic clocks, IGF-1, VO2 max — and wanting measurable data to support their longevity protocol.
Timeline
What to expect.
- 01
Week 1–2
Sleep quality and depth are typically the first changes users notice with Epitalon — more restorative sleep, easier to fall asleep, and improved morning energy. Thymalin's acute immune recalibration may manifest as a subtle improvement in energy and resilience within the first cycle. MOTS-c users often report reduced afternoon fatigue and improved exercise endurance within the first 2 weeks, consistent with its role as an AMPK activator that shifts cells toward more efficient fuel utilisation.
- 02
Week 6
By week 6 of a Mito cycle, body composition shifts start to become noticeable in users who are training — particularly improved metabolic efficiency and reduced post-exercise soreness attributable to SS-31's mitochondrial membrane stabilisation. MOTS-c's insulin-sensitising effects compound over this period. NAD+ repletion begins supporting sirtuin-dependent repair pathways, with some users reporting improved cognitive clarity and workout recovery. Epitalon users who completed a Bioregulator pulse may notice sustained improvements in sleep architecture.
- 03
Week 12
With consistent multi-cycle use, the deeper longevity mechanisms start to express — improved immune function, better cellular health markers, and sustained reduction in biological aging indicators for those tracking them. Thymalin's thymic restoration effect and Epitalon's telomerase activation complement each other across the Bioregulator cycles. Humanin's cytoprotective and anti-apoptotic effects, combined with the mitochondrial membrane stabilisation from SS-31, support neuronal and cellular health at the systemic level after full-stack rotations.
Stacking notes
How this combines.
The six compounds in this stack target distinct but complementary aging pathways and do not meaningfully overlap. Epitalon activates telomerase and regulates circadian output via the pineal gland. Thymalin — a polypeptide bioregulator developed at the St Petersburg Institute of Bioregulation — drives thymic restoration and immune cell repopulation, addressing the immune-senescence axis that Epitalon does not touch. SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilising its structure under oxidative stress. MOTS-c is a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity. NAD-300 replenishes the redox cofactor required for sirtuin and PARP activity. Humanin is a second mitochondrial-derived peptide with anti-apoptotic and neuroprotective properties, providing cytoprotection that complements MOTS-c's metabolic signalling. Because cycle lengths and frequencies differ, these are run in rotation rather than simultaneously — work with a provider to sequence the Bioregulator pulse and Mito cycle across the year.